Xeljanz FDA Warnings & Pulmonary Embolism - The Lyon Firm
« Back to Blog

Xeljanz FDA Warnings & Pulmonary Embolism

Ohio Drug Injury Attorney and Product Liability Lawyer investigates blood clots and pulmonary embolisms, and reviews Xeljanz FDA warnings related to adverse drug effects


The Food and Drug Administration (FDA) is warning about a safety risk reported in a trial of Xeljanz (tofacitinib) in patients with rheumatoid arthritis. The drug trial evaluated the safety of Xeljanz at two different doses (5 mg twice daily or 10 mg twice daily) and assessed the risk of cardiovascular events like pulmonary embolisms and deep vein thrombosis (DVT). Data identified a potential risk of pulmonary embolism and an increased overall mortality in patients taking 10 mg of Xeljanz twice daily.

Pfizer and the FDA have warned adult patients with moderate to severe rheumatoid arthritis as well as doctors of the irregularities in dosage risks. The report underscores the longstanding issue with marketing and selling drugs to the public before such trials can be studied for short and long-term health risks like pulmonary embolism, deep vein thrombosis and other serious complications. Health care professionals and clinical trial researchers are still in the process of studying the drug safety risks of Xeljianz and other rheumatoid arthritis medications.

Joe Lyon is a highly-rated product liability lawyer reviewing Xeljanz FDA warnings and representing injured plaintiffs nationwide in a wide variety of civil litigation claims against Pfizer and other pharmaceutical companies. 


Rheumatoid Arthritis & Xeljanz FDA Warnings


Rheumatoid arthritis (RA) is the most common and disabling type of autoimmune arthritis. Rheumatoid arthritis is a chronic inflammatory disorder that may damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels. As RA progresses, symptoms can spread to all joints including the wrists, knees, ankles, elbows, hips and shoulders. Rheumatoid arthritis occurs when an immune system attacks the lining of the membranes surrounding joints. Medications are commonly prescribed to help patients with pain, mobility inflammation and other aspects of the disease.

In recent years, numerous Rheumatoid Arthritis (RA) patients have reportedly developed complications like paraplegia or limb paralysis after using Xeljanz. The FDA has received multiple adverse event reports for patients taking Xeljanz or Xeljanz XR, and has warned the public of certain risks. The FDA approved Xeljanz labeling changes for risks of appendicitis, interstitial lung disease, pancreatic cancer, and disseminated varicella zoster vaccine virus infection. Risks for lung cancer, breast cancer, melanoma, and prostate cancer were also added to the black box Xeljanz FDA warnings.


Pulmonary Embolism and blood clot risks are also serious complications noted for doctors and patients. Symptoms of a blood clot in your lungs may include:

  • Sudden trouble breathing  
  • Chest pain
  • Coughing up blood
  • Excessive sweating
  • Clammy or bluish colored skin

xeljanz fda warning medical device recall medical device defect lawyer
Xeljanz may raise the risk of blood clots and pulmonary embolism.

If you or a loved one has suffered deep vein thrombosis, a blood clot or pulmonary embolism due to Xeljanz use, and have questions about the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403. You will speak directly with Mr. Lyon, and he will help you answer critical questions regarding Xeljanz FDA warnings.

Contact us today.